A 52-week treatment, multicenter, randomized trial will soon be conducted to evaluate the efficacy and safety of two different doses of QVM149, an association of 3 molecules (indacaterol maleate, glycopyrronium bromide and mometasone furoate) in patients with poorly controlled asthma. This drug is not yet on the market in any country. This new treatment option may provide future patients with severe asthma with an optimized drug combining these 3 molecules.
The approximate total number of recruited patients will be 3155. The study population will consist of male and female adults age ≥ 18 until ≤ 75, with a clinical diagnosis of asthma (GINA 2015 ≥ step 4) for a period of at least 1 year prior to the Screening. Patients must have used inhaled corticosteroids/long acting beta agonist (ICS/LABA) combinations for asthma for at least 1 year and at stable medium or high doses of ICS/LABA for at least 1 month prior to Screening. Please find the full list of inclusion criteria under (Link luxclin study details).
The CHL hospital is one of the recruiting sites with the participation of the CIEC. Additional information on this trial is available on our website under following link ….
More information: www.luxclin.lu/Studies/Details/?c=STP0802LSM
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.